Alvotech amended its credit agreement to add a $75 million term loan facility. GoldenTree Asset Management and existing lenders led the financing. The new capital carries a 12.50% interest rate. This facility matures on December 31, 2027.
The company will use the funds to advance its biosimilar pipeline. Capital will also support global product launches and strategic priorities.
This financing follows an equity capital raise from June 2026. The previous equity raise totaled $165 million. Alvotech now has access to $240 million in new capital. The combined funding strengthens the company’s liquidity and financial position.